STAAR Surgical (STAA) Trial Design is a Lower Bar Than Anticipated - Canaccord Genuity

Canaccord Genuity analyst Jason Mills reiterated a Buy rating and $38.00 price target on STAAR Surgical (NASDAQ: STAA) following FDA’s approval of the firm’s IDE for EVO/EVO+. The firm has made significant strides developing stronger relationships with US Ophthalmologist KOLs making it likely that 300 patients will be enrolled expeditiously.

The analyst stated "we think STAA’s trial design – 300 patients and six-month follow-up – is indeed a much less burdensome pathway than FDA could have requested, thus is an upside surprise to prevailing sentiment on the Street, in our estimation".

For an analyst ratings summary and ratings history on STAAR Surgical click here. For more ratings news on STAAR Surgical click here.

Shares of STAAR Surgical closed at $29.95 yesterday.

You May Also Be Interested In

• STAAR Surgical (STAA) PT Lowered to $28 at Jefferies
• STAAR Surgical (STAA) PT Lowered to $19 at UBS
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating